Nluc Reporter Cell Line - U2932

U2932 is a highly characterized human diffuse large B-cell lymphoma (DLBCL) cell line, originally established from a patient presenting with an aggressive form of the disease. Growing in suspension with a classic lymphoblast morphology, U2932 is particularly significant in hematological research because it represents the activated B-cell (ABC) subtype of DLBCL. This molecular subtype is clinically noted for its constitutive activation of the NF-κB signaling pathway and generally corresponds to a poorer prognosis and higher resistance to standard chemotherapies. The cells robustly express critical B-cell surface antigens, including CD19, CD20, and CD22. The Nluc Reporter Cell Line - U2932 advances this essential oncological model through the stable genetic integration of the NanoLuc (Nluc) reporter gene. NanoLuc is an engineered, exceptionally compact (19.1 kDa) luciferase enzyme derived from the deep-sea shrimp Oplophorus gracilirostris. When catalyzed by its specific substrate, furimazine, it produces a sustained, high-intensity luminescent signal frequently up to 100 times brighter than conventional firefly luciferase.

The integration of the ultra-bright NanoLuc reporter transforms the U2932 cell line into a premier tool for both in vitro analytics and complex preclinical animal modeling, particularly in the rapidly expanding fields of targeted immunotherapy. In standard laboratory environments, the intense luminescent output enables highly sensitive detection of minute cell populations. This provides an ideal platform for high-throughput screening of novel targeted inhibitors—such as those directed against the NF-κB axis—and for evaluating the precise cytotoxicity of emerging immunotherapies, including CD19- or CD20-targeted CAR-T cells and bispecific antibodies. In preclinical animal studies, this reporter line serves as an optimal standard for establishing systemic, disseminated models of human ABC-DLBCL. Following intravenous administration into highly immunodeficient mice, the Nluc-U2932 cells naturally home to and engraft within hematological niches such as the bone marrow, spleen, and lymph nodes. The remarkable sensitivity of NanoLuc-driven bioluminescence imaging (BLI) empowers researchers to non-invasively detect minimal disease burden, map systemic tumor dissemination in real-time, and dynamically track the long-term therapeutic efficacy of experimental treatments in living subjects without relying on destructive endpoint analyses.